530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

Liknande verk

• ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
  av: Konstantinos Venetis, et al.
  Utgiven: (2025-05-01)
• Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
  av: Ioana-Miruna Stanciu, et al.
  Utgiven: (2023-03-01)
• Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from Turkey
  av: Cangür C, et al.
  Utgiven: (2026-01-01)
• Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis
  av: Yuan Liu, et al.
  Utgiven: (2025-10-01)
• Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
  av: Yun Wu, et al.
  Utgiven: (2024-04-01)